Document is current
Any future updates will be listed below
-
Authors
Yarnoff, Benjamin
Neary, Maureen P.
Gabriel, Veronica
Ghemmouri, Mehdi
Hodges, Erin N.
Tribaldos, Maribel
Geurtsen, Jeroen
Chit, Ayman
Beuvelet, Matthieu
Soudani, Samira
Musci, Robert
Krilov, Leonard R.
-
Funding
Funding for this research was provided by:
Sanofi
- License Information
-
More Information
Article History
Received: 5 December 2025
Accepted: 21 January 2026
First Online: 26 February 2026
Declarations
:
: Maureen P. Neary, Veronica Gabriel, Mehdi Ghemmouri, Erin N. Hodges, Matthieu Beuvelet, Samira Soudani, Ayman Chit, Maribel Tribaldos, and Jeroen Geurtsen are employees of Sanofi and may hold shares and/or stock options in the company. Benjamin Yarnoff and Robert Musci are salaried employees of Evidera, Inc. and are not allowed to accept renumeration from any clients for their services. Leonard R. Krilov has served on advisory boards for Sanofi, Merck, and Pfizer and been a clinical trial investigator for each of these sponsors on RSV programs. He did not receive compensation for participation in the development of this manuscript.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
